We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
-13.06%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$1.87B
AUM Growth
-$516M
Cap. Flow
-$95.3M
Cap. Flow %
-5.09%
Top 10 Hldgs %
48.99%
Holding
144
New
7
Increased
8
Reduced
8
Closed
9

Top Buys

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$45.3M
2
FATE icon
Fate Therapeutics
FATE
+$16.6M
3
CYTK icon
Cytokinetics
CYTK
+$11.1M
4
SNTI icon
Senti Biosciences Holdings
SNTI
+$4.46M
5
WVE icon
Wave Life Sciences
WVE
+$3.85M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$60.4M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$18.9M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$18M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$15.9M
5
BLU
BELLUS Health Inc.
BLU
+$12.3M

Sector Composition

Rank Sector Weight
1 Healthcare 89.44%
2 Consumer Discretionary 5.28%
3 Miscellaneous 3.96%
4 Financials 0.87%
5 Consumer Staples 0.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APTX
76
DELISTED
Aptinyx Inc. Common Stock
APTX
$3.41M 0.18%
6,116,493
– –
STOK icon
77
Stoke Therapeutics
STOK
$1.81B
$3.3M 0.18%
250,000
– –
IVVD icon
78
Invivyd
IVVD
$250M
$3.28M 0.18%
1,000,000
– –
CGEM icon
79
Cullinan Oncology
CGEM
$1.31B
$3.21M 0.17%
250,000
– –
RUBY
80
DELISTED
Rubius Therapeutics, Inc
RUBY
$3.15M 0.17%
3,701,580
– –
HOOK
81
DELISTED
HOOKIPA Pharma
HOOK
$3.02M 0.16%
184,962
– –
PRAX icon
82
Praxis Precision Medicines
PRAX
$8.86B
$2.94M 0.16%
80,000
– –
VIGL
83
DELISTED
Vigil Neuroscience
VIGL
$2.89M 0.15%
1,121,191
– –
MIR icon
84
Mirion Technologies
MIR
$3.82B
$2.88M 0.15%
500,000
– –
VOR icon
85
Vor Biopharma
VOR
$1.33B
$2.73M 0.15%
27,500
– –
CINC
86
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$2.58M 0.14%
+137,010
New +$2.62M
SANA icon
87
Sana Biotechnology
SANA
$940M
$2.57M 0.14%
400,000
– –
IMUX icon
88
Immunic
IMUX
$145M
$2.43M 0.13%
70,000
– –
ZYME icon
89
Zymeworks
ZYME
$1.86B
$2.38M 0.13%
450,000
– –
BBIO icon
90
BridgeBio Pharma
BBIO
$13.2B
$2.27M 0.12%
250,000
– –
TCRR
91
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$2.17M 0.12%
750,000
– –
TIL icon
92
Instil Bio
TIL
$49.4M
$2.08M 0.11%
22,500
– –
SNTI icon
93
Senti Biosciences Holdings
SNTI
$9.37M
$2.07M 0.11%
105,556
+55,556
+111% +$4.46M
ADAG
94
Adagene
ADAG
$200M
$2.07M 0.11%
1,000,000
– –
IMMP
95
Immutep
IMMP
$48.6M
$2.03M 0.11%
1,000,000
– –
YI
96
111 Inc
YI
$29.3M
$1.99M 0.11%
96,635
– –
NEXI
97
DELISTED
NexImmune, Inc. Common Stock
NEXI
$1.93M 0.1%
48,000
– –
LENZ
98
LENZ Therapeutics
LENZ
$133M
$1.93M 0.1%
100,000
– –
HARP
99
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$1.91M 0.1%
100,000
– –
FUSN
100
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$1.87M 0.1%
750,000
– –
2 3
4
5 6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q2 2022 Portfolio in Review

As of Q2 2022, Artal Group held 144 positions worth $1.87B, down 22% from $2.39B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Artal Group withdrew a net $95.3M in Q2 2022, closing 9 positions and reducing 8 holdings. Its most notable exit was Protagonist Therapeutics, an estimated $18.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 91% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

Against the trend, Artal Group opened a new position in CinCor Pharma, Inc. Common Stock worth $2.58M.

  • Artal Group's largest Q2 2022 buy was CinCor Pharma, Inc. Common Stock: 137,010 shares worth $2.58M.
  • Artal Group added most to Scholar Rock in Q2 2022, an estimated $45.3M increase.
  • Artal Group's biggest Q2 2022 reduction was argenx, cutting an estimated $60.4M.
  • Artal Group fully exited Protagonist Therapeutics in Q2 2022, selling an estimated $18.9M.
  • Artal Group's ten largest holdings make up 49% of its $1.87B portfolio in Q2 2022.
  • Artal Group opened 7 new positions and closed 9 in Q2 2022.
  • Artal Group's portfolio value fell 22% quarter-over-quarter to $1.87B.

Based on Artal Group's 13F filing for Q2 2022, filed 11 Aug 2022.